This article takes about 4 minutes to read

CURE Basics - 3x Leverage on a Defensive Sector

CURE (Direxion Daily Healthcare Bull 3X Shares) targets 3x the daily return of the Health Care Select Sector Index. Launched June 15, 2011 by Direxion. Direxion's fact sheet as of June 30, 2026 lists an expense ratio of 0.94%. As of the same date, the index's top holdings were Eli Lilly (16.56%), Johnson & Johnson (10.67%), AbbVie (7.76%), UnitedHealth Group (6.59%), and Merck (5.54%).

CURE's defining feature is the contradiction of defensive sector times leverage. Healthcare is recession-resistant (people visit doctors regardless of economy), but 3x leverage substantially undermines that stability.

Liquidity is more limited than TQQQ or SOXL, but is unlikely to be a problem at typical retail order sizes.

The key question: does healthcare's lower volatility make 3x leverage safer? The answer is nuanced. Decay is lower, but so are returns. And -70% drawdowns are still possible.

Healthcare Sector Characteristics

Healthcare is a classic defensive sector with a beta below the market average (1.0). Drug demand is stable regardless of economic cycles, and aging populations provide structural demand growth.

Annualized volatility is said to be ~14-17%, at or slightly below S&P 500's 15-18%. Much lower than technology (20-25%) or semiconductors (28-35%). This lower volatility directly reduces CURE's decay.

Sector-specific risks include drug pricing regulation, patent cliffs (generic competition), clinical trial failures, and FDA regulatory changes. Around the 2016 election, healthcare fell sharply on drug pricing fears.

Demographics provide a tailwind: 65+ populations spend far more on healthcare than younger cohorts. This structural growth supports CURE's long-term case.

The Defensive Times Leverage Contradiction

The idea that healthcare is stable so 3x leverage is safe is wrong. Decay occurs whenever volatility is non-zero. At 15% volatility, annual decay is -3 × (0.15)² = -6.75%.

This is far below SOXL (-27%) or LABU (-36.75%), but healthcare's annual return is also lower (~+10-12%, below technology). Expected 3x return: 30-36%. After decay: 23-29%.

Compared to SPXL: S&P 500 3×10% - 7.7% = 22.3%. Healthcare 3×11% - 6.75% = 26.25%. CURE outperforms SPXL by ~4% annually, but sector concentration risk makes this margin debatable.

The fundamental contradiction: leveraging eliminates defensiveness. A -15% healthcare decline can become a drop of more than -40% in CURE. That is not defensive by any definition.

Decay Rate Comparison - Lowest Among Sector 3x ETFs

Comparing decay rates: CURE (healthcare, σ≈15%): -6.75%. SPXL (S&P 500, σ≈16%): -7.7%. FAS (financials, σ≈22%): -14.5%. TECL (technology, σ≈21%): -13.2%. SOXL (semiconductors, σ≈30%): -27%. LABU (biotech, σ≈35%): -36.75%.

CURE has the lowest decay of the six ETFs compared. Lower decay means the underlying return is more efficiently amplified to 3x. Over 10 years, CURE's cumulative decay is ~-50% vs SOXL's ~-95%.

CURE can be characterized as a low-risk, medium-return leveraged ETF. Potentially +23-26% annual returns. Its risk-return profile differs from TQQQ's.

But the drawdowns along the way can still be severe. CURE is relatively better than other sector 3x ETFs, not absolutely safe.

Why CURE Is Relatively Better

First, the lowest volatility decay of the six compared. At -6.75% annually, the underlying's +10-12% return comfortably offsets it. Second, drawdowns tend to be shallower than those of TQQQ, SOXL, or LABU. A fall to -70% needs +233% to recover, versus +1,900% after a fall to -95%.

Third, structurally supported long-term growth from aging populations, medical technology advances, and emerging market healthcare access expansion.

However, relatively better does not mean safe. A -70% drawdown would turn $10,000 into $3,000. Most investors find this intolerable regardless of relative comparisons.

Among the six ETFs compared, CURE carries less risk than the other sector 3x ETFs only in relative terms; it is still a 3x leveraged product with all the inherent dangers that entails.

Portfolio Positioning

Strategy 1: Stability allocation within a leveraged portfolio. TQQQ 15% + CURE 10% + cash 75% combines technology's explosiveness with healthcare's stability.

Strategy 2: Defensive rotation during recession fears. Shifting from TQQQ/SOXL to CURE aims to maintain leverage while reducing downside. Healthcare has tended to outperform during recessions, so CURE may hold up relatively well.

Strategy 3: Long-term dollar-cost averaging, leveraging low decay and stable sector growth. Monthly contributions can help smooth out volatility. But prepare for large drawdowns along the way.

Understanding the structure of the pharmaceutical industry improves the quality of your healthcare sector investment decisions.